Search results
Results from the WOW.Com Content Network
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs).
The use of valsartan in pregnancy is avoided due to the potential risk of fetal toxicity. [11] The U.S. Food and Drug Administration has a black box warning for valsartan/hydrochlorothiazide use during pregnancy. [2] The use of hydrochlorothiazide is avoided in those with anuria or severe kidney disease. [12]
Iron deficiency anemia in pregnancy can lead to an increased risk of premature delivery, low birth weight and increased risk of perinatal mortality. [ 64 ] The Recommended Dietary Allowance (RDA) suggests 27 mg of iron a day which would account for normal iron losses, iron used by the fetus and related tissues during gestation and increased ...
Hypertensive disorders during pregnancy constitute a significant risk factor for maternal and fetal outcomes, necessitating antihypertensive treatment. However, current data concerning the safety of in utero exposure to antihypertensive medication are controversial.
Sacubitril/valsartan is co-crystallized sacubitril and valsartan, in a one-to-one molar ratio. One sacubitril/valsartan complex consists of six sacubitril anions, six valsartan dianions, 18 sodium cations, and 15 molecules of water, resulting in the molecular formula C 288 H 330 N 36 Na 18 O 48 ·15H 2 O and a molecular mass of 5748.03 g/mol ...
Women who have high blood pressure and had complications in their pregnancy have three times the risk of developing cardiovascular disease compared to women with normal blood pressure who had no complications in pregnancy. Monitoring pregnant women's blood pressure can help prevent both complications and future cardiovascular diseases. [32] [33]
The two graphics illustrate sampling distributions of polygenic scores and the predictive ability of stratified sampling on polygenic risk score with increasing age. + The left panel shows how risk—(the standardized PRS on the x-axis)—can separate 'cases' (i.e., individuals with a certain disease, (red)) from the 'controls' (individuals without the disease, (blue)).
There is a risk that the drug is toxic to fetuses throughout the second and third trimesters. Group 9 There is a risk that the drug causes prenatal complications or abnormalities. Group 10 There is a risk that the drug causes hormone specific action on the human fetus. Group 11 There is a known risk that the drug is a mutagen/carcinogen.